PDF(Pubmed)
Abstract：
BACKGROUND: Alu hypomethylation is a common epigenetic process that promotes genomic instability with aging phenotypes, which leads to type 2 diabetes mellitus (type 2 DM). Previously, our results showed significantly decreased Alu methylation levels in type 2 DM patients. In this study, we aimed to investigate the longitudinal changes in Alu methylation levels in these patients.
RESULTS: We observed significantly decreased Alu methylation levels in type 2 DM patients compared with normal (p = 0.0462). Moreover, our findings demonstrated changes in Alu hypomethylation over a follow-up period within the same individuals (p < 0.0001). A reduction in Alu methylation was found in patients with increasing HbA1c levels (p = 0.0013) and directly correlated with increased HbA1c levels in type 2 DM patients (r = -0.2273, p = 0.0387).
CONCLUSIONS: Alu methylation in type 2 DM patients progressively decreases with increasing HbA1c levels. This observation suggests a potential association between Alu hypomethylation and the underlying molecular mechanisms of elevated blood glucose. Furthermore, monitoring Alu methylation levels may serve as a valuable biomarker for assessing the clinical outcomes of type 2 DM.
RESULTS: We observed significantly decreased Alu methylation levels in type 2 DM patients compared with normal (p = 0.0462). Moreover, our findings demonstrated changes in Alu hypomethylation over a follow-up period within the same individuals (p < 0.0001). A reduction in Alu methylation was found in patients with increasing HbA1c levels (p = 0.0013) and directly correlated with increased HbA1c levels in type 2 DM patients (r = -0.2273, p = 0.0387).
CONCLUSIONS: Alu methylation in type 2 DM patients progressively decreases with increasing HbA1c levels. This observation suggests a potential association between Alu hypomethylation and the underlying molecular mechanisms of elevated blood glucose. Furthermore, monitoring Alu methylation levels may serve as a valuable biomarker for assessing the clinical outcomes of type 2 DM.
摘要：
背景：Alu低甲基化是一种常见的表观遗传过程，可促进衰老表型的基因组不稳定性，导致2型糖尿病（2型DM）。以前,我们的结果显示2型DM患者的Alu甲基化水平显著降低.在这项研究中,我们旨在研究这些患者Alu甲基化水平的纵向变化.
结果：我们观察到2型DM患者的Alu甲基化水平明显低于正常（p=0.0462）。此外，我们的研究结果表明,在同一个体的随访期内,Alu低甲基化发生了变化(p<0.0001).在HbA1c水平升高的患者中发现Alu甲基化降低（p=0.0013），并且与2型DM患者中HbA1c水平升高直接相关（r=-0.2273，p=0.0387）。
结论：2型DM患者的Alu甲基化随着HbA1c水平的升高而逐渐降低。该观察表明Alu低甲基化与血糖升高的潜在分子机制之间存在潜在关联。此外，监测Alu甲基化水平可作为评估2型DM临床结局的有价值的生物标志物.
结果：我们观察到2型DM患者的Alu甲基化水平明显低于正常（p=0.0462）。此外，我们的研究结果表明,在同一个体的随访期内,Alu低甲基化发生了变化(p<0.0001).在HbA1c水平升高的患者中发现Alu甲基化降低（p=0.0013），并且与2型DM患者中HbA1c水平升高直接相关（r=-0.2273，p=0.0387）。
结论：2型DM患者的Alu甲基化随着HbA1c水平的升高而逐渐降低。该观察表明Alu低甲基化与血糖升高的潜在分子机制之间存在潜在关联。此外，监测Alu甲基化水平可作为评估2型DM临床结局的有价值的生物标志物.
